Cognition Therapeutics Inc (CGTX)

Aug 03, 2025

Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News

Aug 03, 2025

Aug 02, 2025

How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News

Aug 02, 2025

Aug 02, 2025

What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News

Aug 02, 2025

Aug 02, 2025

What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com

Aug 02, 2025

Aug 02, 2025

Does Cognition Therapeutics Inc. stock perform well during market downturnsGet exclusive access to premium stock research - Jammu Links News

Aug 02, 2025

Aug 02, 2025

Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - Jammu Links News

Aug 02, 2025

Aug 01, 2025

What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - Jammu Links News

Aug 01, 2025

Aug 01, 2025

Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - TipRanks

Aug 01, 2025

Jul 30, 2025

Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance

Jul 30, 2025

Jul 29, 2025

Published on: 2025-07-29 20:05:06 - metal.it

Jul 29, 2025

Jul 29, 2025

Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it

Jul 29, 2025

Jul 29, 2025

New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times

Jul 29, 2025

Jul 29, 2025

How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it

Jul 29, 2025

Jul 29, 2025

Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire

Jul 29, 2025

Jul 29, 2025

Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan

Jul 29, 2025

Jul 29, 2025

Cognition Therapeutics shares rise 3.50% premarket after PTC Therapeutics' FDA approval of Sephience. - AInvest

Jul 29, 2025

Jul 25, 2025

What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional

Jul 25, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics reports positive results for Alzheimer’s drug By Investing.com - Investing.com South Africa

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq

Jul 21, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times

Jul 21, 2025